Methods and compositions for wound treatment

Patent metadata

Field	Value
Publication number	US-9238068-B2
Application number	US-201414158775-A
Country	US
Kind code	B2
Filing date	Jan 17, 2014
Priority date	Dec 21, 2010
Publication date	Jan 19, 2016
Grant date	Jan 19, 2016

Abstract

The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.

First claim

What is claimed is:

1. A method for treatment of an open wound in a subject, comprising administering to the open wound a composition comprising a carrier, a hemostatic agent, and a wound targeting moiety comprising an antibody specific to a cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope, wherein the carrier is conjugated to the antibody, wherein the carrier contains the hemostatic agent, and wherein the antibody facilitates local delivery of the hemostatic agent to wound tissue by binding to an exposed cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope, wherein the exposed cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope is exposed upon wounding of the subject, and wherein the hemostatic agent is a self-assembling peptides having hemostatic activity.

2. The method of claim 1 , wherein the antibody binds to an exposed extracellular cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope.

3. The method of claim 1 , wherein exposing the cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope results from collagen denaturation.

4. The method of claim 1 , wherein the self-assembling peptide creates a hydrogel.

5. A method for treatment of an internal wound in a subject, comprising administering to the site of the internal wound a composition comprising a carrier containing a hemostatic agent and conjugated to a wound targeting moiety comprising an antibody specific to a cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope, wherein the antibody facilitates local delivery of the hemostatic agent to injured tissue by binding to a cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope that is exposed upon wounding of the subject, and wherein the hemostatic agent is a self-assembling peptides having hemostatic activity.

6. The method of claim 5 , wherein the antibody binds to an exposed extracellular cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope.

7. The method of claim 5 , wherein exposing the cryptic tripeptide arginine-glycine-aspartic acid (RGD) epitope results from collagen denaturation.

8. The method of claim 6 , wherein the self-assembling peptide creates a hydrogel.

Assignees

• Leidos Inc

Inventors

• Dresios John
• Griffey Richard

Classifications

• C07K16/18

  against material from animals or humans · CPC title

• A61K47/6811

  the drug being a protein or peptide, e.g. transferrin or bleomycin · CPC title

• A61K47/42

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61K38/02

  Peptides of undefined number of amino acids; Derivatives thereof · CPC title